证券代码：600276 证券简称：恒瑞医药 公告编号：临 2024-037 江苏恒瑞医药股份有限公司 第九届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）第九届监事会第六次会议 于 2024 年 4 月 16 日以通讯方式召开。本次会议应到监事 3 人，实到监事 3 人。 会议召开符合《公司法》《公司章程》的规定。公司全体 3 名监事认真审议并通 过了以下议案： 一、《公司 2023 年年度报告全文及摘要》（详见上海证券交易所网站： http://www.sse.com.cn） 赞成：3 票 反对：0 票 弃权：0 票 与会监事对公司董事会编制的《公司 2023 年年度报告全文及摘要》进行了 认真审核，一致认为： 1、公司 2023 年年度报告全文及摘要的编制和审议程序符合法律、法规、公 司章程及有关管理制度的规定； 2、公司 2023 年年度报告全文及摘要的内容和格式符合中国证监会和上海证 券交易所的有关规定，所载资料不存在任何虚假记载、误导性陈述或者重 ...

2023年度，作为江苏恒瑞医药股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》《公司 章程》及《独立董事年报工作制度》等的规定和要求，在工作中认真履行职责， 积极出席相关会议，认真审议各项议案，对公司重大事项发表客观、审慎、公正 的事前认可或独立意见，积极维护公司整体利益及全体股东的合法权益。现将本 人2023年度履行职责情况述职如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 本人孙金云，1972 年生，博士研究生学历，副教授。现任复旦大学管理学 院企业管理系副教授、复旦青年创业家教育与研究发展中心主任、复旦大学管理 学院大健康创业与人才发展中心执行主任，兼任派斯林数字科技股份有限公司、 广东小崧科技股份有限公司独立董事。2023 年 2 月起任公司独立董事。 （二）独立性说明 本人未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独立董 事管理办法》《上海证券交易所上市公司自律监 ...

江苏恒瑞医药股份有限公司 审计报告 苏亚审〔2024〕616 号 审计机构：苏亚金诚会计师事务所（特殊普通合伙） 1 审 计 报 告 江苏恒瑞医药股份有限公司全体股东： 一、审计意见 我们审计了江苏恒瑞医药股份有限公司（以下简称恒瑞医药）财务报表，包括 2023 年 12 月 31 日的合并资产负债表及资产负债表，2023 年度的合并利润表及利 润表、合并现金流量表及现金流量表、合并所有者权益变动表及所有者权益变动表 以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公 允反映了恒瑞医药 2023 年 12 月 31 日的财务状况以及 2023 年度的经营成果和现金 流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则，我们独立于恒瑞医药，并履行了职业道德方面的其 他责任。我们相信，我们获取的审计证据是充分、适当的，为发表审计意见提供了 基础。 三、关键审计事项 地 址：江苏省南京市建邺区泰山路 159 号正太中心 A 座 ...

Financial Performance - Revenue in 2023 reached RMB 22.82 billion, a year-on-year increase of 7.26%[16] - Net profit attributable to shareholders of the listed company in 2023 was RMB 4.30 billion, up 10.14% year-on-year[16] - Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses in 2023 was RMB 4.14 billion, a year-on-year increase of 21.46%[16] - Operating cash flow in 2023 surged to RMB 7.64 billion, a 504.12% increase compared to the previous year[16] - Basic earnings per share in 2023 were RMB 0.68, an increase of 11.48% compared to the previous year[17] - Weighted average return on equity in 2023 was 10.99%, an increase of 0.10 percentage points compared to the previous year[17] - Net cash flow from operating activities surged by 504.12% to 7,643,665,074.52 yuan in 2023[160] - Net cash flow from investing activities increased by 213.18% to RMB 1.22 billion, primarily due to the recovery of bank financial products and structured deposits[150] - Net cash flow from financing activities decreased by 886.42% to RMB -3.14 billion, mainly due to the repayment of accounts receivable factoring financing[150] - The oncology segment generated RMB 12.22 billion in revenue, a 7.99% increase year-over-year, with a gross margin of 91.82%[151] - Domestic sales accounted for RMB 21.76 billion, a 6.49% increase year-over-year, with a gross margin of 85.53%[151] - International sales declined by 20.83% to RMB 616.92 million, with a gross margin increase of 7.57 percentage points[151] - The company's total R&D investment in 2023 was 6,150,007,119.05 yuan, accounting for 26.95% of total revenue, with 19.45% of R&D investment being capitalized[159] - The company's sales expenses increased by 3.12% to 7,577,175,913.92 yuan in 2023 compared to the previous year[158] - The company's monetary funds increased by 37.29% to 20,746,104,943.19 yuan, accounting for 47.38% of total assets[163] - The company's top five customers contributed 222,332.29 million yuan in sales, accounting for 9.74% of total annual sales[157] - The company's top five suppliers accounted for 29.20% of total annual procurement, amounting to 95,712.47 million yuan[157] - The company's raw material and packaging costs for anti-tumor products decreased by 8.92% to 558,023,804.33 yuan in 2023[155] - The company's development expenditure increased by 48.27% to 2,492,549,260.85 yuan in 2023[163] - The company's R&D investment in 2023 reached 6.15 billion yuan, accounting for 26.95% of sales revenue, supporting project development and innovation[170] - The oncology treatment segment achieved revenue of 12.22 billion yuan, with a gross margin of 91.82%, an increase of 1.63 percentage points year-over-year[169] - The analgesic and anesthesia segment generated revenue of 3.74 billion yuan, with a gross margin of 85.22%, up 1.68 percentage points year-over-year[169] - The contrast agent segment reported revenue of 2.74 billion yuan, with a gross margin of 61.14%, a decrease of 4.38 percentage points year-over-year[169] Dividend and Shareholder Information - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares (tax included) to all shareholders, based on the share capital on the dividend record date (excluding shares held in the company's repurchase account)[3] Corporate Governance and Compliance - The company has no instances of non-operational fund occupation by controlling shareholders or related parties, nor any violations in external guarantee decision-making processes[4] - The company is committed to strict compliance and high-quality standards, ensuring the safety and efficacy of its products[118] R&D and Innovation - R&D investment in 2023 totaled RMB 6.15 billion, with RMB 4.95 billion expensed[24] - Revenue from innovative drugs in 2023 reached RMB 10.64 billion (including tax, excluding external licensing income), a year-on-year increase of 22.1%[24] - Three Class 1 innovative drugs and four Class 2 new drugs were approved for marketing in 2023[24] - By the end of 2023, the company had 15 Class 1 innovative drugs and 4 Class 2 new drugs approved for marketing in China[24] - The company has detailed risks related to R&D innovation and industry policies in its 2023 annual report, urging investors to review the management discussion and analysis section[5] - The company has over 50 innovative oncology products in clinical trials, focusing on extending the 5-year survival rate of cancer patients in China[115] - The company has a comprehensive R&D platform covering multiple therapeutic areas, including oncology, autoimmune diseases, and metabolic diseases[119] - The company employs a differentiated R&D strategy, utilizing a fully electronic R&D project management platform that covers the entire drug development lifecycle[121] - The company is actively engaged in real-world studies to generate more evidence-based medical data, leveraging the low cost and broad scope of such studies[115] - The company is focusing on early-stage target discovery and source innovation to accelerate the development of differentiated cancer treatments[115] - The company has established a comprehensive R&D process focusing on unmet clinical needs, exploring international frontiers, and selecting high-potential drug targets with First-in-class/Best-in-class potential[122] - The company has a rigorous clinical trial process divided into Phase I, II, and III, with Phase I focusing on safety, Phase II on efficacy and safety, and Phase III on confirming therapeutic effects and safety[123] - The company has established a high-throughput, automated antibody sequence analysis and modification platform, enabling iterative optimization of antibody sequences[136] - The company has developed a new HART-IgG platform on top of the existing Hot-Ig bispecific antibody platform, enabling more diverse drug functionalities[136] - The company's translational medicine team supports target selection, early discovery, drug combination, indication exploration, clinical biomarker exploration, companion diagnostic development, and post-marketing drug resistance mechanism research[138] - The company has established a series of in vitro and in vivo experimental systems, including cell biology, molecular biology, immunology, in vivo efficacy, IHC, bioinformatics, and bioanalysis platforms[137] - The company has optimized and extended its antibody screening platforms, including hybridoma, phage display, yeast display, and single B-cell cloning, and established a new nanobody immune library[136] - The company has strengthened its antibody engineering platform, accumulating experience in independently optimized screening schemes to meet internal antibody screening needs[136] - The company has successfully advanced 11 novel and differentiated ADC molecules into clinical trials, with HER2 ADC product SHR-A1811 and TROP2 ADC product SHR-A1921 rapidly progressing to Phase III clinical studies[140] - Two PROTAC molecules are currently in clinical research stages, and the PD-L1/TGFβ fusion protein drug SHR-1701 is advancing multiple Phase III clinical studies[140] - The company has developed a high-throughput single B-cell sequencing antibody discovery platform, which offers advantages in screening cycles and antibody sequence diversity[142] - The HOT-Ig platform, a proprietary bispecific antibody technology, has one molecule in clinical research and two molecules in IND development[142] - The ADC platform has multiple molecules in preclinical and clinical development, with two novel bispecific ADC projects entering IND research stages[142] - The NK cell therapy platform is being developed with Fc modifications and novel NK agonist screening to create NK cell engagers (NKCE) for new bispecific/trispecific NK cell therapies[143] - The high-throughput display platform features a fully human phage library and semi-synthetic library with a capacity of hundreds of billions, used for high-throughput antibody screening[143] - The PROTAC platform has two projects in clinical research and multiple projects covering various solid and hematologic tumors, exploring undruggable targets[143] - The AI molecular design platform combines CADD and AIDD technologies for small molecule drug discovery and optimization, and uses AI for antibody discovery and optimization[143] - The bioinformatics platform integrates multi-omics data (genomics, transcriptomics, proteomics, single-cell transcriptomics, spatial transcriptomics) for target discovery and biomarker identification[144] Clinical Trials and Drug Approvals - Newly approved innovative drug Adebelizumab significantly improved overall survival and contributed to rapid revenue growth[25] - Three innovative drugs, including Ruweiluamine, Darxili, and Henggeliezin, were included in the national medical insurance catalog with an average price reduction of 65%, expanding revenue contribution[25] - Sales of generic drugs decreased by CNY 702 million and CNY 911 million due to the impact of centralized procurement[25] - Camrelizumab combined with chemotherapy for advanced NSCLC achieved a 5-year OS rate of 31.2%, significantly higher than the chemotherapy group's 19.3%[28] - Adebelizumab combined with chemotherapy for ES-SCLC achieved a median OS of 15.3 months and a 3-year OS rate of 21.1%, reducing the risk of death by 27%[28] - The company published 119 significant research results in top international journals, with a cumulative impact factor of 1393.45[29] - Pyrotinib combined with trastuzumab and docetaxel for HER2-positive advanced breast cancer achieved a median PFS of 24.3 months, with an impact factor of 105.7[29] - Camrelizumab combined with apatinib for advanced hepatocellular carcinoma achieved a median OS of 22.1 months, the longest among published data for first-line treatments[29] - The company has 11 novel and differentiated ADC molecules approved for clinical trials, with the anti-HER2 ADC product SHR-A1811 showing competitive data in a global Phase I study for advanced solid tumors[31] - The company's KRAS G12D inhibitor, the first lipid-based KRAS G12D inhibitor globally, successfully entered Phase I clinical trials and was selected for an oral presentation at the 2023 ESMO Congress[31] - In 2023, the company received approval for 7 innovative drug production licenses, 5 improved new drug production licenses, and 4 generic drug production licenses[32] - The company submitted 246 domestic patent applications and 79 international PCT applications, with 99 domestic and 76 foreign patents granted in 2023[33] - The company secured 5 external licensing deals totaling over $4 billion USD in 2023[34] - The company's first international multicenter Phase III study for camrelizumab combined with apatinib in advanced liver cancer met its primary endpoint, with the BLA submitted to the US FDA and a target review date of May 31, 2024[35] - The company presented 57 studies on 8 anti-tumor innovative drugs at the 2023 ASCO Annual Meeting, including 2 oral presentations and 3 poster discussions[36] - At the 2023 ESMO Congress, the company had 35 research results from 13 anti-tumor innovative drugs, including 2 selected for preferred oral presentations and 5 for short oral presentations[36] - The company passed a total of 42 official inspections by domestic and international regulatory authorities, including the US FDA, across its subsidiaries[37] - The company introduced over 600 core talents in 2023, including more than 150 with doctoral degrees[40] - The company's "Double Ai" combination (camrelizumab + apatinib) for first-line treatment of unresectable hepatocellular carcinoma was published in *The Lancet* with an impact factor of 168.9[41] - The company's camrelizumab + chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma was published in *JAMA* with an impact factor of 120.7[41] - The company's pyrotinib + trastuzumab + docetaxel for first-line treatment of HER2+ metastatic breast cancer was published in *BMJ* with an impact factor of 105.7[41] - The company's dalpiciclib + fulvestrant for HR+/HER2- advanced breast cancer was published in *Nature Medicine* with an impact factor of 82.9[42] - The company's adebrelimab + chemotherapy for first-line treatment of extensive-stage small cell lung cancer was published in *The Lancet Oncology* with an impact factor of 51.1[41] - The company's fluzoparib for maintenance treatment of platinum-sensitive recurrent ovarian cancer was published in *Journal of Clinical Oncology* with an impact factor of 45.3[41] - SHR-A1811, a HER2 ADC, is in Phase III clinical trials for HER2-positive breast cancer adjuvant therapy, HER2-low recurrent/metastatic breast cancer, and HER2-positive recurrent/metastatic breast cancer with or without pertuzumab[45] - SHR-A1811 is also in Phase III clinical trials for HER2-positive advanced gastric or gastroesophageal junction cancer after first-line anti-HER2 treatment failure[46] - SHR-1819, an IL-4Rα inhibitor, is in Phase II clinical trials for atopic dermatitis and moderate-to-severe chronic rhinosinusitis with nasal polyps[46] - SHR-1918, an ANGPTL3 inhibitor, is in Phase II clinical trials for hyperlipidemia with poor lipid control and homozygous familial hypercholesterolemia[46] - HRS-5965, a Factor B inhibitor, is in Phase II clinical trials for IgA nephropathy[46] - SHR-1905, an anti-TSLP antibody, is in Phase II clinical trials for chronic rhinosinusitis with nasal polyps[46] - SHR-2010, a MASP-2 inhibitor, is in Phase II clinical trials for IgA nephropathy[46] - SHR-1906, a CTGF inhibitor, is in Phase II clinical trials for idiopathic pulmonary fibrosis[46] - Adebelimab (PD-L1) is in Phase II clinical trials in combination with SHR-A1921 (TROP2 ADC) for advanced solid tumors[46] - Adebelimab is also in Phase II clinical trials in combination with neoadjuvant chemotherapy for locally advanced resectable esophageal squamous cell carcinoma[46] - SHR-A1811 is being developed as a HER2 ADC for various indications including HER2-positive advanced solid tumors, HER2-low advanced breast cancer, and HER2-expressing gynecological malignancies, both as monotherapy and in combination with other treatments[47] - SHR-2009, a HER3 ADC, is being tested in combination with SHR-A1811 and HRS-8080 for ER-positive unresectable or metastatic breast cancer, and in combination with SHR-8068 or bevacizumab for advanced solid tumors[47] - HRS-8080, a SERD, is being evaluated in combination with SHR-A1811 and SHR-2009 for ER-positive unresectable or metastatic breast cancer, and with dalpiciclib for ER-positive, HER2-negative unresectable or metastatic breast cancer[47] - SHR-8068, a CTLA-4 inhibitor, is being studied in combination with SHR-A1811 and adebrelimab for HER2-abnormal advanced solid tumors, and with SHR-2009 for advanced solid tumors[47] - Adebrelimab, a PD-L1 inhibitor, is being tested in combination with SHR-2002 and bevacizumab, and with SHR-8068 and bevacizumab for advanced solid tumors[48] - SHR-2002, a PVRIG-TIGIT inhibitor, is being evaluated as monotherapy or in combination with adebrelimab for advanced malignancies[48] - HRS-9815 and HRS-4357, both PSMA-targeting radiopharmaceuticals, are being developed for prostate cancer diagnosis and metastatic castration-resistant prostate cancer, respectively[48] - SHR-3167 is being developed as a monotherapy for diabetes[48] - HRS-5041, an AR-PROTAC, is being tested as a monotherapy for metastatic castration-resistant prostate cancer[48] - SHR-2017 is entering Phase I clinical trials for the prevention of bone-related events in solid tumor bone metastases and multiple myeloma[48] - Camrelizumab (carrelizumab) has 9 approved indications, with 20 clinical study results presented at international academic conferences, and 275 papers published in international journals with a cumulative impact factor of 2640.184[52] - Camrelizumab combined with apatinib for advanced liver cancer achieved an objective response rate (ORR) of 65.5% and a disease control rate (DCR) of 86.2%, with a median progression-free survival (mPFS) of 10.4 months[52] - Camrelizumab combined with famitinib showed an ORR of 41.0% vs 24.1% compared to camrelizumab monotherapy in recurrent or metastatic cervical cancer, with a median PFS of 8.1 months[53] - Camrelizumab combined with chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC) achieved a 5-year overall survival (OS) rate of 31.2%, significantly higher than the 19.3% in the chemotherapy group[54] - Camrelizumab combined with chemotherapy for advanced squamous NSCLC showed a 4-year OS rate of 33.9%, nearly 20% higher than the 14.3% in the chemotherapy group[54] - Camrelizumab combined with apatinib for advanced liver cancer received FDA BLA acceptance in July 2023[52] - Camrelizumab combined with famitinib for recurrent or metastatic cervical cancer had its new drug application accepted by CDE in December 2023[52] - Camrelizumab's receptor occupancy rate remained above 95% on day 22 post-administration, with a relatively short half-life to reduce immune-related adverse effects[52] - Camrelizumab's CARES310 study on advanced liver cancer was published in The Lancet with an impact factor of 168.9, the highest among all domestic PD-1 products[52] - Camrelizumab's NACI study on locally advanced cervical cancer showed an ORR of 98% and a pathological complete response (pCR) rate of 38% in the full analysis set (FAS) population[53] - Pyrotinib significantly improved median PFS (22.0 months vs 6.9 months) and median OS (59.9 months vs 31.2 months) compared to lapatinib in HER2

江苏恒瑞医药股份有限公司 独立董事工作制度 第一章 总则 第一条 为规范江苏恒瑞医药股份有限公司（以下简称"公司"）独立董事的行 为，充分发挥独立董事在公司治理中的作用，根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司独立董事管理办法》（以下简称"《独董办法》"）、 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规、规范性文件的规定，结合《江苏恒瑞医药股份 有限公司章程》（以下简称"《公司章程》"）的要求和实际情况，制订本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及主要股东、 实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独立客观判断 关系的董事。独立董事应当独立履行职责，不受公司及公司主要股东、实际控制 人等单位或个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照相关法律法 规、中国证券监督管理委员会（以下简称"中国证监会"）规定、上海证券交易 所（以下简称"上交所"）业务规则和《公司章程》的规定，认真履行职责，在 董事会中发挥参与决策、监督制衡、专业咨询作用，维护公司整体利益 ...

环境、社会及管治 (ESG) 报告 江苏恒瑞医药股份有限公司 2023 江苏恒瑞医药股份有限公司 2023 年环境、社会及管治报告 恒于管治 强化责任管理 恒于创新 坚守产品责任 恒于人本 尊重员工价值 恒于奉献 履行社会责任 恒于绿色 守护生态家园 目录 | 4 | 关于本报告 | 恒于管治， | | 恒于绿色， | | | --- | --- | --- | --- | --- | --- | | 5 | 管理层致辞 | 强化责任管理 | | 守护生态家园 | | | 6 | 关于恒瑞医药 | | | | | | 10 | 2023 年恒瑞医药所 | 18 | 1.1 完善公司治理 | 32 | 2.1 完善环境管理 | | | 获奖项及荣誉 | 20 | 1.2 加强责任管理 | 35 | 2.2 规范资源使用 | | 14 | 亮点 ESG 绩效 | 23 | 1.3 夯实合规管理 | 42 | 2.3 控制污染排放 | | | | 29 | 1.4 坚持党建引领 | 45 | 2.4 践行绿色运营 | | 恒于创新， | | 恒于人本， | | | --- | --- | --- | --- | | ...

目 录 1、专项审计报告 2、附表 委托单位：江苏恒瑞医药股份有限公司 审计单位：苏亚金诚会计师事务所（特殊普通合伙） 联系电话：025-83231630 关于对江苏恒瑞医药股份有限公司 2023 年度非经营性资金占用及其他关联资金 往来情况的专项说明 关于江苏恒瑞医药股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 我们接受委托，审计了江苏恒瑞医药股份有限公司（以下简称"恒瑞医 药" ）2023 年 12 月 31 日的合并资产负债表及资产负债表、2023 年度的合并 利润表及利润表、合并现金流量表及现金流量表、合并所有者权益变动表及所 有者权益变动表以及财务报表附注，并于 2024 年 4 月 16 日出具了苏亚审〔2024〕 616 号无保留意见审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》〔证监会公告[2022]26 号〕和上海证券交易所 相关披露的要求，恒瑞医药编制了后附的 2023 年度非经营性资金占用及其他关 联资金往来情况汇总表（以下简称汇总表）。如实编制和对外披露汇总表并确保 其真实、合法及完整是恒瑞医 ...

江苏恒瑞医药股份有限公司 审计委员会实施细则 第一章 总则 第一条 为强化董事会决策功能,做到事前审计、专业审计,确 保董事会对经理层的有效监督,完善公司治理结构,根据《中华 人民共和国公司法》《上市公司治理准则》《上海证券交易所 股票上市规则》《公司章程》《董事会议事规则》及其他有关 规定,公司特设立董事会审计委员会,并制定本实施细则。 第二条 董事会审计委员会是董事会按照股东大会决议设立的 专门工作机构,主要职能是协助董事会独立地审查公司财务状 况及内部监控系统的执行情况及效果，负责对公司经营管理和 投资业务进行合规性控制，对公司内部审计工作结果进行审查 和监督，以及与内部审计师和外部审计师的独立沟通、监督和 核查工作。 第二章 人员组成 第三条 审计委员会成员由三至七名董事组成，应当为不在公 司担任高级管理人员的董事，其中独立董事应当过半数，并由 独立董事中会计专业人士担任召集人。 第四条 审计委员会委员由董事长、二分之一以上独立董事或 者全体董事的三分之一提名,并由董事会选举产生。 第五条 审计委员会设主任委员（召集人）一名,由作为会计专 业人士的独立董事委员担任,负责主持委员会工作；主任委员 在委员 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2024-038 江苏恒瑞医药股份有限公司 2023 年度利润分配方案公告 每股分配比例：每股派发现金股利 0.2 元（含税）。 本次利润分配股本以分红派息登记日股本（扣除公司股份回购专用证券 账户持有股数）为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 一、利润分配方案内容 经苏亚金诚会计师事务所（特殊普通合伙）审计，公司2023年度实现归属于 上市公司普通股股东的净利润为4,302,435,930.05元。截至2023年12月31日，公 司可供股东分配的利润为28,802,770,314.90元。经董事会决议，公司2023年度 拟以分红派息登记日股本（扣除公司股份回购专用证券账户持有股数）为基数分 配利润。本次利润分配方案如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）董事会会议的召开、审议和表决情况 上市公司拟向全体 ...

一、《公司 2023 年度董事会工作报告》 赞成：9 票 反对：0 票 弃权：0 票 二、《公司 2023 年年度报告全文及摘要》（详见上海证券交易所网站： http://www.sse.com.cn） 赞成：9 票 反对：0 票 弃权：0 票 本议案已经公司董事会审计委员会审议通过。 三 、《 公 司 2024 年 第 一 季 度 报 告 》（详见上海证券交易所网站： http://www.sse.com.cn） 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2024-036 江苏恒瑞医药股份有限公司 第九届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）第九届董事会第七次会议 于 2024 年 4 月 16 日以现场结合通讯方式召开。本次会议应到董事 9 人，实到董 事 9 人。会议召开符合《公司法》《公司章程》的规定。公司全体董事认真审议 并通过以下议案： 本议案已经公司董事会战略委员会审议通过。 五、《公司 2024 年度"提质增效重回报 ...